Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (557)	2/14/1999 1:56:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1073

ReCap is a great resource. It is frequently off a bit or missing stuff, however..... "This strategy has enabled the development of a broad pipeline of royalty bearing product opportunities led by CP358,774, an anti-cancer compound, which is currently in large scale Phase II trials funded and managed by Pfizer." biz.yahoo.com Friday November 6, 12:18 pm Eastern Time Pfizer unveils raft of early stage Rx drugs NEW YORK, Nov 6 (Reuters) - Pfizer Inc. disclosed on Friday a plethora of early-stage experimental drugs, which the company said it hopes will make Pfizer the world's premier pharmaceutical company by the early 21st century. Meanwhile, Pfizer executives said they were comfortable that they will deliver diluted per share earnings of $1.95 to $2.00 from continuing operations, excluding nonrecurring and special items, in 1998. And they said Pfizer would likely have earnings growth in the fourth quarter of 1998 stronger than that seen in the third quarter. In an unusual move, Pfizer senior scientist John Niblack, unveiled the names and characteristics of many drugs that are currently in preclinical animal testing or being studied in human Phase I and Phase II clinical trials. Pfizer said that at least several of the more promising early-stage compounds were cancer drugs being developed in collaboration with OSI Pharmaceuticals Inc (Nasdaq:OSIP - news). (snip)